Cost-Consequences and Health Outcomes of Emtricitabine and Tenofovir Alafenamide (FTC/TAF): A Novel Two-Drug, Fixed-Dose Combination for Human Immunodeficiency Virus (HIV) Patients
Altice F, Dejesus E. Cost-Consequences and Health Outcomes of Emtricitabine and Tenofovir Alafenamide (FTC/TAF): A Novel Two-Drug, Fixed-Dose Combination for Human Immunodeficiency Virus (HIV) Patients. Open Forum Infectious Diseases 2016, 3: 495. DOI: 10.1093/ofid/ofw172.358.Peer-Reviewed Original Research